ORION CORPORATION
STOCK EXCHANGE RELEASE / MAJOR SHAREHOLDER ANNOUNCEMENTS
7 January 2026 at 08.30 EET
Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)
Orion Corporation has received a disclosure under Chapter 9, Section 5 of the Securities Market Act, according to which the total number of Orion shares owned directly, indirectly and through financial instruments by BlackRock, Inc. and its funds increased on 5 January 2026 above five (5) per cent of Orion Corporation’s total shares.
Total positions of BlackRock, Inc. and its funds subject to notification:
% of shares and voting rights
(total of point A)
% of shares and voting rights through financial instruments
(total of point B)
Total of both in % (points A + B)Total number of shares and voting rights of issuerResulting situation on the date on which threshold was crossed or reached4.97% shares
Below 5% voting rights
0.02% shares
Below 5% voting rights
5.00% shares
Below 5% voting rights
141,134,278 shares
744,770,339 voting rights
Position of previous notification (if applicable)Below 5% shares
Below 5% voting rights
Below 5% shares
Below 5% voting rights
Below 5% shares
Below 5% voting rights
Notified details of the resulting situation on the date on which the threshold was crossed:
Point A: Shares and voting rights:
Class/type of shares
ISIN code
Number of shares and voting rights% of shares and voting rights Direct (SMA 9:5)Indirect (SMA 9:6 and 9:7)Direct (SMA 9:5)Indirect (SMA 9:6 and 9:7)FI0009014377 7,025,834 shares
Below 5% voting rights
4.97% shares
Below 5% voting rights
POINT A SUBTOTAL7,025,834 shares
Below 5% voting rights
4.97% shares
Below 5% voting rights
Point B: Financial instruments according to SMA 9:6a:Type of financial instrumentExpiration dateExercise / Conversion PeriodPhysical or cash settlementNumber of shares and voting rights% of shares and voting rightsAmerican Depositary Receipt (US68628Y1047)N/AN/APhysical200 shares
Below 5% voting rights
0.00% shares
Below 5% voting rights
Securities LentN/AN/APhysical41,878 shares
Below 5% voting rights
0.02% shares
Below 5% voting rights
POINT B SUBTOTAL42,078 shares
Below 5% voting rights
0.02% shares
Below 5% voting rights
Orion CorporationLiisa Hurme
President and CEO
Mikko Kemppainen
General Counsel
Contact person:
Tuukka Hirvonen, Investor Relations, Orion Corporation
tel. +358 10 426 2721
Publisher:
Orion Corporation
Communications
Orionintie 1A, FI-02200 Espoo, Finland
www.orionpharma.com
Orion is a globally operating Nordic pharmaceutical company – a builder of well-being for over a hundred years. We develop, manufacture and market human and veterinary pharmaceuticals and active pharmaceutical ingredients. Orion has an extensive portfolio of proprietary and generic medicines and consumer health products. The core therapy areas of our pharmaceutical R&D are oncology and pain. Proprietary products developed by Orion are used to treat cancer, neurological diseases and respiratory diseases, among others. In 2024 Orion’s net sales amounted to EUR 1,542 million and the company employed about 3,700 professionals worldwide, dedicated to building well-being. Orion’s A and B shares are listed on Nasdaq Helsinki.
